Schwaches Statement vom CEO.
interessant im Zusammenhang wieviel Umsatz sie damit machen obwohl mittlerweile untersagt.
Wegovy and Ozempic, along with rival Eli Lilly's (LLY) Mounjaro and Zepbound, were in a shortage for much of the last two years, with a Food and Drug Administration policy allowing compounding pharmacies to make and sell versions of the drugs based on the same active ingredient while they were in short supply.
However, when the FDA said earlier this year that Ozempic and Wegovy were no longer in a shortage, it warned compounding pharmacies had until mid-May before the agency would pursue enforcement actions.
interessant im Zusammenhang wieviel Umsatz sie damit machen obwohl mittlerweile untersagt.
Wegovy and Ozempic, along with rival Eli Lilly's (LLY) Mounjaro and Zepbound, were in a shortage for much of the last two years, with a Food and Drug Administration policy allowing compounding pharmacies to make and sell versions of the drugs based on the same active ingredient while they were in short supply.
However, when the FDA said earlier this year that Ozempic and Wegovy were no longer in a shortage, it warned compounding pharmacies had until mid-May before the agency would pursue enforcement actions.
Gegendarstellung könnte helfen. Werden das ja nicht unkommentiert lassen.#82W(A2QMYY)
37,01 +2,5%Hims & Hers Health Inc
37,01 €
07:30:02+0,91 €
+2,52 %Hoch: 38,38 €
Tief: 36,06 €
- Symbol:
- 82W
- WKN:
- A2QMYY
- ISIN:
- US4330001060
IRANISCHE RAKETEN ABGEFEUERT
